Want to join the conversation?
$AMGN files an application with the FDA seeking clearance for a single once a month 420 mg injection of its cholesterol fighter Repatha (evolocumab), which is currently available in a single-use 140 mg/mL prefilled autoinjector which requires three subcu injection of 420 mg. The FDA cleared Repatha, a PCSK9 inhibitor, on Aug. 27, for lowering LDL-C
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.